Home › NDC Lookup › Ingredients › Potassium Chloride › 00245-0360-30
🧴image loading
(from DailyMed)

Klor-Con potassium chloride 1.5 g Powder, For Solution, 30 packets — NDC 0245-0360-30 (Billing 00245-0360-30)

by Upsher-Smith Laboratories, LLC · 30 PACKET in 1 CARTON / 1 POWDER, FOR SOLUTION in 1 PACKET

This is a package of 30 packets of Klor-Con potassium chloride 1.5 g Powder, For Solution from Upsher-Smith Laboratories, LLC, marketed since Oct 2017 and currently FDA-listed; retail pharmacies pay about $0.4700 per packet (NADAC). It is the main listing for this product, which comes in 2 package sizes.

NDC 00245-0360-30
🏷️ FDA NDC (as labeled) 0245-0360-30 billing pads the labeler segment with a zero
This package
Contains30 packets Cost per ea$0.4700 NADAC Per package$14.10 / 30 powder Pack sizes2 compare ↓
Also priced by: Medicaid pays $1.23/unit · Part D plans $1.72/unit — full pricing hub ↓
Main listing for product 0245-0360 · Also comes in: 100 packets 0245-0360-01
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0245-0360-30 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
0245 labeler · 0360 product · 30 package
Package marketed since
Oct 23, 2017
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Billing quantity
30 EA per package
Barcode (UPC-A, from the NDC)
3 0245036030 8
Medicaid fills, this package
9,008 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026
⚠️
Other active recalls for Potassium Chloride (different manufacturers) — 6 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class I · Oct 29, 2025 — Labeling: Label Error on Declared Strength-The overwrap label may incorrectly identify the product as POTASSIUM CHLORIDE Inj. 10 mEq instead of POTASSIUM CHLORIDE Inj. 20 mEq (Otsuka ICU Medical LLC) · FDA recall D-0181-2026
Class I · Oct 29, 2025 — Labeling: Label Error on Declared Strength-The overwrap label may incorrectly identify the product as POTASSIUM CHLORIDE Inj. 10 mEq instead of POTASSIUM CHLORIDE Inj. 20 mEq (Otsuka ICU Medical LLC) · FDA recall D-0180-2026
Class I · Feb 13, 2025 — Labeling: Label Error on Declared Strength. Overwrap labeled as Potassium Chloride Inj 10 mEq may contain flexible containers of Potassium Chloride Inj 20 mEq (ICU Medical, Inc.) · FDA recall D-0268-2025
Class I · Feb 13, 2025 — Labeling: Label Error on Declared Strength. Cases labeled POTASSIUM CHLORIDE 20 mEq, may contain flexible containers with overwrap mislabeled as 10 mEq. The correct dosage strength of 20 mEq is printed on the labeling affixed to the product flexible container. (ICU Medical, Inc.) · FDA recall D-0267-2025
Class II · Jan 30, 2025 — Failed Dissolution Specifications. (The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories) · FDA recall D-0221-2025
Class I · Jun 25, 2024 — Failed Dissolution Specifications (Amerisource Health Services LLC) · FDA recall D-0619-2024
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0245-0360-30
Product NDC 0245-0360
11-digit billing NDC 00245036030
NCPDP billing unit EA — each (per item)
RxCUI 1867544, 1867547
UNII 660YQ98I10
Application # ANDA209662
SPL Set ID e61a4522-b91d-400a-952c-6f035e4610dd
Established class (EPC) Osmotic Laxative; Potassium Salt
Mechanism of action Osmotic Activity
Physiologic effect Increased Large Intestinal Motility; Inhibition Large Intestine Fluid/Electrolyte Absorption
Chemical class Potassium Compounds
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2017-10-23
Route ORAL
Dosage form POWDER, FOR SOLUTION
Substance POTASSIUM CHLORIDE
TE code (Orange Book) AA · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 79700030003015
GPI class Klor-Con
GCN Seq No 001262
GCN 03404
HICL code 000549
Ingredient (HICL) Potassium Chloride
HIC1 code C
Therapeutic class — broad (HIC1) Electrolyte Balance/Metabolism/Nutrition
HIC2 code C1
Therapeutic class — intermediate (HIC2) Drugs Affecting Electrolyte Balance
HIC3 code C1D
Therapeutic class — specific (HIC3) Potassium Replacement
AHFS code 40:12.00.00
AHFS class Replacement Preparations
FDB label name KLOR-CON 20 MEQ PACKET
FDB brand name Klor-Con
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 001262
  • GCN: 03404
  • GPI-14 (Medi-Span): 79700030003015
  • HICL (First Databank): 000549
  • AHFS class code: 40:12.00.00
  • RxCUI (RxNorm): 1867544
Why two NDCs? The FDA registers this code as 0245-0360-30 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00245-0360-30. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Potassium class.

Drug family (ATC) Potassium, Electrolyte solutions
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name KLOR-CON 20 MEQ PACKET Ingredient Potassium Chloride
📗 Our plain-language guide HelloPharmacist
  • It treats and prevents low potassium. Doctors often use it when you take diuretics or lose fluids through diarrhea or vomiting and food alone isn't enough. The injection is used in...
  • Take tablets and capsules with meals, not on an empty stomach, to protect your stomach. Powders and liquids need to be diluted first. Follow your prescriber's directions and keep y...
  • The most common issue is stomach upset. Taking it with food helps. Call your doctor if you have severe vomiting, belly pain, swelling or bleeding, since that can mean an ulcer or b...
  • Check with me first. Blood pressure medicines such as ACE inhibitors and ARBs, spironolactone, and NSAIDs can raise potassium. Triamterene and amiloride should be avoided with it.
📖 Read our full Potassium Chloride guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.470 $14.10 / 30 powder
Medicaid paysCMS SDUD · 12 mo $1.23 $36.99 / 30 powder
Medicare drug plans payPart D · Q2 2026 $1.72 $51.55 / 30 powder
NADAC price history (per ea) — tap or hover for the price & month
Oct 2021 Dec 2025 Apr 2026 Sep 2026 $4.097 $0.470
▼ Down 85% over the last 14 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
00245-0360-01 0245-0360-01 100 PACKET in 1 CARTON / 1 POWDER, FOR SOLUTION in 1 PACKET $0.4700 / ea $47.00 2017-10-23 — Active
00245-0360-30 You're viewing this Main listing 30 PACKET in 1 CARTON / 1 POWDER, FOR SOLUTION in 1 PACKET $0.4700 / ea $14.10 2017-10-23 — Active

This pack effectively ties for the lowest per-ea cost of the 2 priced pack sizes ($0.4700 NADAC).

In Medicaid, this is the most-dispensed pack of this product — about 84% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package contains 30 packets — 30 packet in 1 carton / 1 powder, for solution in 1 packet.
How does this package differ from NDC 00245-0360-01?
Both are Klor-Con potassium chloride 1.5 g Powder, For Solution — the drug itself is identical. This page's package is the 30 packets one, while NDC 00245-0360-01 is the 100 packets package.
What NDC number is used to bill for this package of Klor-Con potassium chloride 1.5 g Powder, For Solution?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Klor-Con 1.5 gthis 00245-0360-30 Upsher-Smith 30 packets $0.470 AA Availability likely —
Potassium Chloride 1.5 g/1.77g 69543-0451-10 Virtus 100 packets $0.594 AA Discontinued +26%
Potassium Chloride 1.5 g/1.58g 00603-1554-04 Endo 100 pouches $0.624 — Availability likely +33%
Potassium Chloride 1.5 g/1.58g 23155-0856-76 Heritage 30 pouches $0.624 AA Discontinued +33%
Potassium Chloride 1.5 g/1.77g 42806-0094-01 Epic 100 packets $0.624 AA Availability likely +33%
Potassium Chloride 1.5 g/1.58g 60219-1617-03 Amneal 30 pouches $0.624 AA Availability likely +33%
Potassium Chloride 1.5 g/1.58g 60687-0855-27 American 30 pouches $0.624 AA Availability likely +33%
Potassium Chloride 1.5 g/1.58g 64380-0875-69 Strides 30 pouches $0.624 AA Availability likely +33%
Potassium Chloride for Oral Solution 1.5 g/1.58g 70069-0823-01 Somerset 1.58 g $0.624 AA Availability likely +33%
Potassium Chloride 1.5 g/1.58g 72603-0407-01 Northstar 1.58 g $0.624 AA Availability likely +33%
Potassium Chloride 1.5 g/1.58g 72888-0024-07 Advagen 30 pouches $0.624 AA Availability likely +33%
Potassium Chloride 1.5 g/1.58g 81033-0413-01 Kesin 100 pouches $0.624 AA Availability likely +33%
Potassium Chloride 1.5 g/1.54g 43386-0194-30 Lupin 30 pouches $1.994 AA FDA listed +324%
Potassium Chloride for Oral Solution 1.5 g/1.58g 10135-0807-13 Marlex 100 pouches — AA FDA listed —
Potassium Chloride 1.5 g/1.54g 40032-0194-30 Novel 30 pouches — AA FDA listed —
Potassium Chloride 1.5 g/1.57g 53041-0420-49 Guardian 30 pouches — AA FDA listed —
Potassium Chloride for Oral Solution 1.5 g/1.58g 54288-0125-10 BPI 100 pouches — AA FDA listed —
Potassium Chloride 1.5 g/1.58g 64950-0321-01 Genus 100 pouches — — FDA listed —
Potassium Chloride for Oral Solution 1.5 g/1.58g 70010-0071-41 Granules 1.58 g — AA FDA listed —
Potassium chloride 1.5 g/1.56g 70954-0197-20 ANI 30 pouches — AA FDA listed —
Potassium Chloride 1.5 g/1.77g 72162-2310-01 Bryant 100 packets — AA FDA listed —
Potassium Chloride for Oral Solution 1.5 g/1.58g 82983-0403-10 Ajenat 100 pouches — AA FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2017
On the market since
Oct 2017
📍
2026
Currently FDA-listed
9 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerUpsher-Smith Laboratories, LLC
Application holderUPSHER SMITH LABORATORIES LLC
FDA applicationANDA209662 (ANDA)
Labeler code00245
First marketedOct 2017
Product typeHuman Prescription Drug
Portfolio229 products on file

More NDCs from Upsher-Smith Laboratories, LLC labeler code 00245

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration 💊 Dosage Forms and Strengths ⛔ Contraindications ⚠️ Warnings and Cautions 🤒 Adverse Reactions 🔄 Drug Interactions 👥 Use in Specific Populations 🤰 Pregnancy 🧒 Pediatric Use 🧓 Geriatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 🧬 Mechanism of Action 📦 How Supplied / Storage and Handling 📦 Storage and Handling 📋 Description 🧬 Pharmacokinetics 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 75 words ▾

1 INDICATIONS AND USAGE Klor-Con ® powder (potassium chloride) is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. Potassium chloride is a potassium salt indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. ( 1 )

⏱️ Dosage and Administration ~2 min read ▾

2 DOSAGE AND ADMINISTRATION Dilute prior to administration. ( 2.1 , 5.1 ) Monitor serum potassium and adjust dosage accordingly. ( 2.2 , 2.3 ) If serum potassium concentration is <2.5 mEq/L, use intravenous potassium instead of oral supplementation.

( 2.1 ) Treatment of hypokalemia: Adults: Initial doses range from 40 to 100 mEq/day in 2 to 5 divided doses: limit doses to 40 mEq per dose. Total daily dose should not exceed 200 mEq. ( 2.2 ) Pediatric patients aged birth to 16 years old: 2 to 4 mEq/kg/day in divided doses; not to exceed 1 mEq/kg as a single dose or 40 mEq whichever is lower; if deficits are severe or ongoing losses are great, consider intravenous therapy.

Total daily dose should not exceed 100 mEq. ( 2.3 ) Maintenance or Prophylaxis of hypokalemia: Adults: Typical dose is 20 mEq per day. ( 2.2 ) Pediatric patients aged birth to 16 years old: typical dose is 1 mEq/kg/day.

Do not to exceed 3 mEq/kg/day. ( 2.3 )

2.1Administration and Monitoring If serum potassium concentration is <2.5 mEq/L, use intravenous potassium instead of oral supplementation. Monitoring Monitor serum potassium and adjust dosages accordingly. For treatment of hypokalemia, monitor potassium levels daily or more often depending on the severity of hypokalemia until they return to normal.

Monitor potassium levels monthly to biannually for maintenance or prophylaxis. The treatment of potassium depletion, particularly in the presence of cardiac disease, renal disease, or acidosis requires careful attention to acid-base balance, volume status, electrolytes, including magnesium, sodium, chloride, phosphate, and calcium, electrocardiograms and the clinical status of the patient. Correct volume status, acid-base balance and electrolyte deficits as appropriate.

Administration Dilute the contents of 1 packet of potassium chloride for oral solution with 4 ounces of cold water or other beverage [see Warnings and Precautions (5.1) ]. Take with meals or immediately after eating.

2.2Adult Dosing Treatment of hypokalemia: Daily dose range from 40 to 100 mEq. Give in 2 to 5 divided doses: limit doses to 40 mEq per dose. The total daily dose should not exceed 200 mEq in a 24 hour period.

Maintenance or Prophylaxis: Typical dose is 20 mEq per day. Individualize dose based upon serum potassium levels. Studies support the use of potassium replacement in digitalis toxicity.

When alkalosis is present, normokalemia and hyperkalemia may obscure a total potassium deficit. The advisability of use of potassium replacement in the setting of hyperkalemia is uncertain.

2.3Pediatric Dosing Treatment of hypokalemia: Pediatric patients aged birth to 16 years old: The initial dose is 2 to 4 mEq/kg/day in divided doses; do not exceed as a single dose 1 mEq/kg or 40 mEq, whichever is lower; maximum daily doses should not exceed 100 mEq. If deficits are severe or ongoing losses are great, consider intravenous therapy. Maintenance or Prophylaxis Pediatric patients aged birth to 16 years old: Typical dose is 1 mEq/kg/day.

Do not exceed 3 mEq/kg/day.

💊 Dosage Forms and Strengths 50 words ▾

3 DOSAGE FORMS AND STRENGTHS Each packet contains 1.5 g of potassium chloride supplying 20 mEq of potassium and 20 mEq of chloride. Potassium chloride for oral solution, USP 20 mEq: Each packet contains 1.5 g of potassium chloride providing potassium 20 mEq and chloride 20 mEq. ( 3 )

⛔ Contraindications 21 words ▾

4 CONTRAINDICATIONS Klor-Con powder is contraindicated in patients on potassium sparing diuretics. Concomitant use with potassium sparing diuretics. ( 4 )

⚠️ Warnings and Cautions 41 words ▾

5 WARNINGS AND PRECAUTIONS Gastrointestinal Irritation: Dilute before use, take with meals. ( 5.1 )

5.1Gastrointestinal Irritation May cause gastrointestinal irritation. Increased dilution of the solution and taking with meals may reduce gastrointestinal irritation [see Dosage and Administration (2.1) ].

🤒 Adverse Reactions 52 words ▾

6 ADVERSE REACTIONS The most common adverse reactions to oral potassium salts are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea. Most common adverse reactions are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Upsher-Smith Laboratories, LLC at 1-855-899-9180 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

🔄 Drug Interactions 114 words ▾

7 DRUG INTERACTIONS Potassium sparing diuretics: Avoid concomitant use. ( 7.1 ) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7.2 ) Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7.3 )

7.1Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use.

7.2Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy.

7.3Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. Closely monitor potassium in patients on concomitant NSAIDs.

👥 Use in Specific Populations ~2 min read ▾

8 USE IN SPECIFIC POPULATIONS Cirrhosis: Initiate therapy at the low end of the dosing range. ( 8.6 ) Renal Impairment: Initiate therapy at the low end of the dosing range. ( 8.7 )

8.1Pregnancy There are no human data related to use of Potassium Chloride during pregnancy, and animal studies have not been conducted. Potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm. The background risk for major birth defects and miscarriage in the indicated population is unknown.

All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

8.2Lactation Risk Summary The normal potassium ion content of human milk is about 13 mEq per liter. Since potassium from oral supplements such as Potassium Chloride becomes part of the body potassium pool, as long as body potassium is not excessive, the contribution of potassium chloride supplementation should have little or no effect on the level in human milk.

8.4Pediatric Use Clinical trial data from published literature have demonstrated the safety and effectiveness of potassium chloride in children with diarrhea and malnutrition from birth to 16 years.

8.5Geriatric Use Clinical studies of potassium chloride did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

8.6Cirrhotics Patients with cirrhosis should usually be started at the low end of the dosing range, and the serum potassium level should be monitored frequently [see Clinical Pharmacology (12.3) ].

8.7Renal Impairment Patients with renal impairment have reduced urinary excretion of potassium and are at substantially increased risk of hyperkalemia. Patients with impaired renal function, particularly if the patient is on ACE inhibitors, ARBs, or nonsteroidal anti-inflammatory drugs should usually be started at the low end of the dosing range because of the potential for development of hyperkalemia. The serum potassium level should be monitored frequently.

Renal function should be assessed periodically.

🤰 Pregnancy 90 words ▾

8.1Pregnancy There are no human data related to use of Potassium Chloride during pregnancy, and animal studies have not been conducted. Potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm. The background risk for major birth defects and miscarriage in the indicated population is unknown.

All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

🧒 Pediatric Use 29 words ▾

8.4Pediatric Use Clinical trial data from published literature have demonstrated the safety and effectiveness of potassium chloride in children with diarrhea and malnutrition from birth to 16 years.

🧓 Geriatric Use 140 words ▾

8.5Geriatric Use Clinical studies of potassium chloride did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

🆘 Overdosage 212 words ▾

10 OVERDOSAGE

10.1Symptoms The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired or if potassium is administered too rapidly potentially fatal hyperkalemia can result . Hyperkalemia is usually asymptomatic and may be manifested only by an increased serum potassium concentration (6.5 to 8.0 mEq/L) and characteristic electrocardiographic changes (peaking of T-waves, loss of P-waves, depression of S-T segment, and prolongation of the QT-interval).

Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).

10.2Treatment Treatment measures for hyperkalemia include the following: Monitor closely for arrhythmias and electrolyte changes. Eliminate foods and medications containing potassium and of any agents with potassium-sparing properties such as potassium-sparing diuretics, ARBs, ACE inhibitors, NSAIDs, certain nutritional supplements and many others. Administer intravenous calcium gluconate if the patient is at no risk or low risk of developing digitalis toxicity.

Administer intravenously 300 to 500 mL/hr of 10% dextrose solution containing 10 to 20 units of crystalline insulin per 1000 mL. Correct acidosis, if present, with intravenous sodium bicarbonate. Use exchange resins, hemodialysis, or peritoneal dialysis.

In patients who have been stabilized on digitalis, too rapid a lowering of the serum potassium concentration can produce digitalis toxicity.

🧬 Clinical Pharmacology ~1 min read ▾

12 CLINICAL PHARMACOLOGY

12.1Mechanism of Action The potassium ion (K + ) is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity; the transmission of nerve impulses; the contraction of cardiac, skeletal, and smooth muscle; and the maintenance of normal renal function. The intracellular concentration of potassium is approximately 150 to 160 mEq per liter.

The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane. Potassium is a normal dietary constituent, and under steady-state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine.

The usual dietary intake of potassium is 50 to 100 mEq per day.

12.3Pharmacokinetics Based on published literature, the rate of absorption and urinary excretion of potassium from KCl oral solution were higher during the first few hours after dosing relative to modified release KCl products. The bioavailability of potassium, as measured by the cumulative urinary excretion of K + over a 24 hour post dose period, is similar for KCl solution and modified release products. Specific Populations Cirrhotics Based on published literature, the baseline corrected serum concentrations of potassium measured over 3 h after administration in cirrhotic subjects who received an oral potassium load rose to approximately twice that of normal subjects who received the same load.

🧬 Mechanism of Action 133 words ▾

12.1Mechanism of Action The potassium ion (K + ) is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity; the transmission of nerve impulses; the contraction of cardiac, skeletal, and smooth muscle; and the maintenance of normal renal function. The intracellular concentration of potassium is approximately 150 to 160 mEq per liter.

The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane. Potassium is a normal dietary constituent, and under steady-state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine.

The usual dietary intake of potassium is 50 to 100 mEq per day.

📦 How Supplied / Storage and Handling 93 words ▾

16 HOW SUPPLIED/STORAGE AND HANDLING Klor-Con ® powder (potassium chloride for oral solution, USP) is a light orange powder available in one strength as follows: 20 mEq Each packet contains 1.5 g of potassium chloride providing potassium 20 mEq and chloride 20 mEq supplied in: Cartons of 30 packets NDC 0245-0360-30 Cartons of 100 packets NDC 0245-0360-01 Storage Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Dispense in tight, light-resistant container as defined in the USP.

PROTECT from LIGHT.

📦 Storage and Handling 36 words ▾

Storage Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Dispense in tight, light-resistant container as defined in the USP. PROTECT from LIGHT.

📋 Description 92 words ▾

11 DESCRIPTION Potassium chloride is a white crystalline or colorless solid. It is soluble in water and slightly soluble in alcohol. Chemically, potassium chloride is KCl with a molecular mass of 74.55.

Each packet of light orange powder contains 1.5 g of potassium chloride, USP, which is equivalent to potassium 20 mEq and chloride 20 mEq. Each packet of Klor-Con powder contains the following inactive ingredients: FD&C Yellow No. 6, malic acid, neotame, and natural orange flavor (Modified food starch (with added corn syrup), maltodextrin, citric acid, silicon dioxide and natural tocopherols).

🧬 Pharmacokinetics 106 words ▾

12.3Pharmacokinetics Based on published literature, the rate of absorption and urinary excretion of potassium from KCl oral solution were higher during the first few hours after dosing relative to modified release KCl products. The bioavailability of potassium, as measured by the cumulative urinary excretion of K + over a 24 hour post dose period, is similar for KCl solution and modified release products. Specific Populations Cirrhotics Based on published literature, the baseline corrected serum concentrations of potassium measured over 3 h after administration in cirrhotic subjects who received an oral potassium load rose to approximately twice that of normal subjects who received the same load.

📄 Package Label / Principal Display Panel 44 words ▾

PRINCIPAL DISPLAY PANEL - 1.5 g Packet Carton NDC 0245-0360-30 Klor-Con ® Powder (Potassium Chloride for Oral Solution, USP) 20 mEq Orange Flavored Each packet contains: Potassium Chloride 1.5 g 30 Single-Dose Packets Rx only UPSHER-SMITH PRINCIPAL DISPLAY PANEL - 1.5 g Packet Carton

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
9K
Units reimbursed last 4 qtrs
393K
Gross reimbursed last 4 qtrs
$484.6K
Avg / prescription
$53.79
Avg / unit
$1.2331
Latest quarter Q1 2026
972Rx
Medicaid pays / ea
$1.2331
gross reimbursed
vs
NADAC / ea
$0.4700
acquisition cost
=
Spread
+$0.7631
+162% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
43% FFS 57% MCO
Fee-for-service · 3,890 Rx Managed care · 5,118 Rx
State Medicaid map
Alaska: 1,913 units · 261 per 100k residents AK Maine: no data reported ME Washington: 1,661 units · 21.3 per 100k residents WA Idaho: 3,421 units · 174 per 100k residents ID Montana: 1,713 units · 151 per 100k residents MT North Dakota: no data reported ND Minnesota: 15,666 units · 273 per 100k residents MN Wisconsin: 26,039 units · 441 per 100k residents WI Michigan: 1,418 units · 14.1 per 100k residents MI New York: 33,046 units · 169 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 5,028 units · 119 per 100k residents OR Nevada: 6,953 units · 218 per 100k residents NV Wyoming: no data reported WY South Dakota: 937 units · 102 per 100k residents SD Iowa: no data reported IA Illinois: 31,196 units · 249 per 100k residents IL Indiana: 19,048 units · 278 per 100k residents IN Ohio: 44,198 units · 375 per 100k residents OH Pennsylvania: 48,242 units · 372 per 100k residents PA New Jersey: 3,978 units · 42.8 per 100k residents NJ Massachusetts: 4,654 units · 66.5 per 100k residents MA California: 17,619 units · 45.2 per 100k residents CA Utah: 480 units · 14.0 per 100k residents UT Colorado: 20,113 units · 342 per 100k residents CO Nebraska: no data reported NE Missouri: 12,466 units · 201 per 100k residents MO Kentucky: no data reported KY West Virginia: 8,570 units · 484 per 100k residents WV Virginia: 9,232 units · 106 per 100k residents VA Maryland: 6,428 units · 104 per 100k residents MD Connecticut: 397 units · 11.0 per 100k residents CT Rhode Island: 570 units · 52.1 per 100k residents RI Arizona: 8,628 units · 116 per 100k residents AZ New Mexico: 5,726 units · 271 per 100k residents NM Kansas: 1,762 units · 59.9 per 100k residents KS Arkansas: no data reported AR Tennessee: 4,052 units · 56.9 per 100k residents TN North Carolina: 10,433 units · 96.3 per 100k residents NC South Carolina: 932 units · 17.3 per 100k residents SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: 10,263 units · 224 per 100k residents LA Mississippi: no data reported MS Alabama: 1,348 units · 26.4 per 100k residents AL Georgia: 5,655 units · 51.3 per 100k residents GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 14,036 units · 46.0 per 100k residents TX Florida: 5,138 units · 22.7 per 100k residents FL
Units reimbursed · per 100k residents
11.0484
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 West Virginia 484 /100k
2 Wisconsin 441 /100k
3 Ohio 375 /100k
4 Pennsylvania 372 /100k
5 Colorado 342 /100k
6 Indiana 278 /100k
7 Minnesota 273 /100k
8 New Mexico 271 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
30 packets this page00245-0360-30 9,008 Rx · $484,562
100 packets00245-0360-01 1,778 Rx · $108,540
Drug total (last 4 qtrs): 10,786 Rx · 495,499 units · $593,102 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Klor-Con — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Klor-Con. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$654.8K
Claims incl. refills
6.4K
Beneficiaries
5.4K
Spend / beneficiary
$121.97
Spend / claim
$102.71
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for KLOR-CON (this brand).

Top reported reactions

Diarrhoea7,891
Dyspnoea7,887
Nausea7,591
Fatigue7,496
Death5,433
Pneumonia5,272
Asthenia4,883

Reporter sex

108,800 reports

Serious outcomes

Life-threatening6,090
Disabling2,475
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 7,854 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
← 00245-0213-01 · Upsher-Smith 00245-0410-01 · Upsher-Smith →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.